Literature DB >> 19500529

Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections.

Gita Wasan Patel1, Nimish Patel, Asma Lat, Kristen Trombley, Sam Enbawe, Kelli Manor, Raymond Smith, Thomas P Lodise.   

Abstract

This comparison of intermittent versus extended-infusion piperacillin-tazobactam among patients with Gram-negative infections revealed similar mortality and length of stay. Outcomes remained similar when stratified by MIC value.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19500529     DOI： 10.1016/j.diagmicrobio.2009.03.002

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  18 in total

1.  Antimicrobial stewardship.

Authors:  Shira Doron; Lisa E Davidson
Journal:  Mayo Clin Proc       Date:  2011-11       Impact factor: 7.616

2.  Should IV Antibiotics Be Administered by Prolonged Infusion?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2010-05

3.  Importance of infusion volume and pump characteristics in extended administration of ß-lactam antibiotics.

Authors:  Barbara Claus; Franky Buyle; Hugo Robays; Dirk Vogelaers
Journal:  Antimicrob Agents Chemother       Date:  2010-09-07       Impact factor: 5.191

Review 4.  Bloodstream infections in the Intensive Care Unit.

Authors:  Matteo Bassetti; Elda Righi; Alessia Carnelutti
Journal:  Virulence       Date:  2016-01-13       Impact factor: 5.882

5.  Extended Infusion of Piperacillin/Tazobactam in Children.

Authors:  Chad A Knoderer; Lauren C Karmire; Katie L Andricopulos; Kristen R Nichols
Journal:  J Pediatr Pharmacol Ther       Date:  2017 May-Jun

6.  Administration of Extended Infusion Piperacillin-TazobactamWith the Use of Smart Pump Technology.

Authors:  Megan L Maddox; Erica C DeBoer; Rhonda J Hammerquist
Journal:  Hosp Pharm       Date:  2014-05

Review 7.  Appraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections--proceedings and data from the Gram-Negative Resistance Summit.

Authors:  Marin H Kollef; Yoav Golan; Scott T Micek; Andrew F Shorr; Marcos I Restrepo
Journal:  Clin Infect Dis       Date:  2011-09       Impact factor: 9.079

Review 8.  Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.

Authors:  Mordechai Grupper; Joseph L Kuti; David P Nicolau
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

9.  Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.

Authors:  Erin M Winstead; Patrick D Ratliff; Ryan P Hickson; Joseph E Mueller; William R Judd
Journal:  Int J Clin Pharm       Date:  2016-06-22

10.  Extended-Infusion versus standard-infusion piperacillin-tazobactam for sepsis syndromes at a tertiary medical center.

Authors:  Scott R Cutro; Robert Holzman; Yanina Dubrovskaya; Xian Jie Cindy Chen; Tania Ahuja; Marco R Scipione; Donald Chen; John Papadopoulos; Michael S Phillips; Sapna A Mehta
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.